2.95

6.88% 0.19

After Hours: 2.91 -0.04 -1.36%

Revelation Biosciences Inc (REVB)

Overview News Price History Financials Discussions Forecast Stock Split

Revelation Biosciences Inc stock is traded at $2.95, with a volume of 48,677. It is up +6.88% in the last 24 hours and down -33.26% over the past month. Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Previous Close:

$2.76

Open:

$2.7

24h Volume:

48,677

Relative Volume:

0.21

Market Cap:

$2.67M

Revenue:

Net Income/Loss:

$-15.52M

P/E Ratio:

-0.1588

EPS:

-18.58

Net Cash Flow:

$-16.61M

1W Performance:

-13.24%

1M Performance:

-33.26%

6M Performance:

-78.57%

1Y Performance:

-91.91%

1-Day Range:

$2.70

$3.13

1-Week Range:

$2.36

$3.45

52-Week Range:

$2.36

$60.80

Revelation Biosciences Inc Stock (REVB) Company Profile

Name

Revelation Biosciences Inc

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

650-800-3717

Address

4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

REVB's Discussions on Twitter

Compare REVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REVB Revelation Biosciences Inc	2.95	2.67M	0	-15.52M	-16.61M	-18.58
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Revelation Biosciences Inc Stock (REVB) Latest News

Mar 17, 2025

REVB stock touches 52-week low at $2.71 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 17, 2025

REVB stock touches 52-week low at $2.71 amid sharp annual decline - Investing.com Australia

Mar 17, 2025

Revelation Biosciences: Gemini priming attenuates inflammatory response in PBMCs - TipRanks

Mar 17, 2025

Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells - Marketscreener.com

Mar 17, 2025

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire

Mar 17, 2025

Mar 13, 2025

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire

Mar 13, 2025

Revelation Biosciences Unveils Growth Strategy at Prestigious Roth Conference - StockTitan

Mar 13, 2025

Mar 10, 2025

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ

Mar 06, 2025

Feb 26, 2025

Revelation Biosciences stock hits 52-week low at $3.26 By Investing.com - Investing.com South Africa

Feb 26, 2025

Revelation Biosciences stock hits 52-week low at $3.26 - Investing.com

Feb 26, 2025

Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients - Marketscreener.com

Feb 26, 2025

Revelation doses first patient in PRIME Phase 1b clinical study - TipRanks

Feb 26, 2025

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire

Feb 26, 2025

Artificial Intelligence (AI) News Live Feed - StockTitan

Feb 26, 2025

Feb 24, 2025

Revelation Biosciences gets continued listing approval from Nasdaq - MSN

Feb 24, 2025

Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement - Marketscreener.com

Feb 24, 2025

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire

Feb 24, 2025

Feb 13, 2025

Larchmont broker accused of years-long insider trading scheme - Westfair Online

Feb 13, 2025

Feb 11, 2025

Allergic Rhinitis Market Expected to rise, 2034 | Regeneron, - openPR

Feb 11, 2025

Feb 03, 2025

Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews

Feb 03, 2025

Jan 30, 2025

Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL

Jan 30, 2025

Allergic Rhinitis Market to Show Remarkable Growth Trends from - openPR

Jan 30, 2025

Revelation Biosciences stock hits 52-week low at $0.28 - MSN

Jan 30, 2025

Jan 29, 2025

REVB Start 1B Trial and Announces Split - MSN

Jan 29, 2025

REVB: Phase 1b Begins and Nasdaq Compliance Regained - Research Tree

Jan 29, 2025

Jan 28, 2025

Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn

Jan 28, 2025

Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn

Jan 28, 2025

Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn

Jan 28, 2025

Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn

Jan 28, 2025